Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 12:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 874 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cervix Carcinoma Clear all
Completed Not applicable Interventional

Pelvic Floor Muscle Training in Treating Urinary Incontinence in Gynecologic Cancer Survivors

NCT01806350
View directory record Official record
Conditions
Cervical Cancer, Endometrial Cancer, Ovarian Epithelial Cancer, Ovarian Germ Cell Tumor, Uterine Sarcoma, Vulvar Cancer
Interventions
questionnaire administration, standard follow-up care, educational intervention
Other · Procedure
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
30 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Mar 7, 2013 · Synced Oct 20, 2026, 12:38 AM EDT
Terminated Not applicable Interventional Results available

Fluorine F 18 EF5 PET/CT Imaging in Patients With Locally Advanced or Recurrent/Metastatic Cervical Cancer

NCT00978874
View directory record Official record
Conditions
Cervical Cancer
Interventions
fludeoxyglucose F 18, fluorine F 18 EF5
Radiation
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 25, 2021 · Synced Oct 20, 2026, 12:38 AM EDT
Completed Phase 2 Interventional Results available

Cetuximab and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer

NCT00101192
View directory record Official record
Conditions
Cervical Cancer
Interventions
cetuximab, cisplatin
Biological · Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
18
States / cities
Burbank, California • Los Angeles, California • Savannah, Georgia + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2014 · Synced Oct 20, 2026, 12:38 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Patient Satisfaction & Quality Of Life in Patients With Cervical Cancer

NCT00473798
View directory record Official record
Conditions
Psychosocial, Cervical Cancer
Interventions
Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
1,938 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2020
U.S. locations
4
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 12, 2020 · Synced Oct 20, 2026, 12:38 AM EDT
Active, not recruiting Not applicable Interventional

e-Health Intervention (Day-by-Day) for the Management of Fear of Progression in Women With Stage III or IV Gynecologic Cancer: A Pilot Study

NCT05786456
View directory record Official record
Conditions
Malignant Female Reproductive System Neoplasm, Stage III Cervical Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Uterine Corpus Cancer AJCC v8, Stage III Vaginal Cancer AJCC v8, Stage III Vulvar Cancer AJCC v8, Stage IV Cervical Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Uterine Corpus Cancer AJCC v8, Stage IV Vaginal Cancer AJCC v8, Stage IV Vulvar Cancer AJCC v8
Interventions
Discussion, Informational Intervention, Media Intervention, Questionnaire Administration, Telephone-Based Intervention
Procedure · Other · Behavioral
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 20, 2026, 12:38 AM EDT
Active, not recruiting Phase 1 Interventional

NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy

NCT03589339
View directory record Official record
Conditions
Radiotherapy, Immunotherapy, Microsatellite Instability-High Solid Malignant Tumour, Metastasis From Malignant Tumor of Liver, Squamous Cell Carcinoma of Head and Neck, Metastasis From Malignant Tumor of Cervix, Metastatic Renal Cell Carcinoma, Metastasis From Malignant Melanoma of Skin (Disorder), Metastatic Triple-Negative Breast Carcinoma, Metastatic NSCLC, Metastasis From Malignant Tumor of Bladder (Disorder)
Interventions
NBTXR3, SABR, Nivolumab, Pembrolizumab
Drug · Radiation
Lead sponsor
Nanobiotix
Industry
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
13
States / cities
San Francisco, California • Tampa, Florida • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2025 · Synced Oct 20, 2026, 12:38 AM EDT
Not listed Phase 1 Interventional

Cisplatin and Radiation Therapy Followed by Paclitaxel and Carboplatin in Treating Patients With Stage IB-IVA Cervical Cancer

NCT01295502
View directory record Official record
Conditions
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Stage IB Cervical Cancer AJCC v6 and v7, Stage IIA Cervical Cancer AJCC v7, Stage IIB Cervical Cancer AJCC v6 and v7, Stage IIIA Cervical Cancer AJCC v6 and v7, Stage IIIB Cervical Cancer AJCC v6 and v7, Stage IVA Cervical Cancer AJCC v6 and v7
Interventions
Carboplatin, Cisplatin, External Beam Radiation Therapy, Internal Radiation Therapy, Paclitaxel
Drug · Radiation
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
14
States / cities
Orange, California • Hartford, Connecticut • New Britain, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2019 · Synced Oct 20, 2026, 12:38 AM EDT
Completed Phase 1 Interventional

A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies

NCT03652077
View directory record Official record
Conditions
Cervical Cancer, Gastric Cancer, Stomach Cancer, Gastroesophageal Junction Cancer, Esophageal Cancer, Hepatocellular Carcinoma, Melanoma, Uveal Melanoma, Merkel Cell Carcinoma, Mesothelioma, MSI, Non-small Cell Lung Cancer, NSCLC, Ovarian Cancer, Squamous Cell Carcinoma of the Head and Neck, Small Cell Lung Cancer, Renal Cell Carcinoma, RCC, Triple-negative Breast Cancer, Urothelial Carcinoma, Mismatch Repair Deficiency
Interventions
INCAGN02390
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
4
States / cities
Los Angeles, California • Jackson, Mississippi • Hackensack, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2021 · Synced Oct 20, 2026, 12:38 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Human Papillomavirus (HPV) Self-Sampling Options to Promote Equity

NCT07214506
View directory record Official record
Conditions
Uterine Cervical Neoplasms, HPV Testing, Pap Smear
Interventions
Human papillomavirus Self-collection, Usual Care
Other
Lead sponsor
University of Arizona
Other
Eligibility
30 Years to 64 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 20, 2026, 12:38 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors

NCT05572684
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumors, Microsatellite Instability Low, Microsatellite Instability High, Microsatellite Stable, Ovarian Cancer, Gastric Cancer, Colo-rectal Cancer, Esophageal Cancer, Endometrial Cancer, Head Neck Cancer, Cervical Cancer, Lung Cancer
Interventions
NC410, pembrolizumab
Drug
Lead sponsor
NextCure, Inc.
Industry
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
17
States / cities
Tucson, Arizona • Aurora, Colorado • Edgewood, Kentucky + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 20, 2026, 12:38 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

International PPB/DICER1 Registry

NCT03382158
View directory record Official record
Conditions
Pleuropulmonary Blastoma, Sertoli-Leydig Cell Tumor, DICER1 Syndrome, Cystic Nephroma, Wilms Tumor, Pineoblastoma, Renal Sarcoma, Nodular Hyperplasia of Thyroid, Nasal Chondromesenchymal Hamartoma, Ciliary Body Medulloepithelioma, Neuroblastoma, Pituitary Cancer, Embryonal Rhabdomyosarcoma, Ovarian Sarcoma, Gynandroblastoma, Thyroid Carcinoma, Embryonal Rhabdomyosarcoma of Vagina (Diagnosis), Embryonal Rhabdomyosarcoma of Uterus (Diagnosis), Embryonal Rhabdomyosarcoma of Cervix
Interventions
Not listed
Lead sponsor
Children's Hospitals and Clinics of Minnesota
Other
Eligibility
0 Minutes to 100 Years
Enrollment
3,400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2035
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 30, 2025 · Synced Oct 20, 2026, 12:38 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Cervical Cancer Screening Project Part C

NCT01575444
View directory record Official record
Conditions
Cervical Cancer
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
25 Years to 70 Years · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Oct 20, 2026, 12:38 AM EDT
Withdrawn Not applicable Interventional

Assessment of EGFR Genomic Alterations as Prognostic Markers in Cervical Cancer

NCT00298064
View directory record Official record
Conditions
Cervical Cancer, Cervix
Interventions
Tissue Repository
Genetic
Lead sponsor
University of New Mexico
Other
Eligibility
Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jul 5, 2023 · Synced Oct 20, 2026, 12:38 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Evaluation of the Q-Pad hrHPV Test System for Identifying Precancer

NCT07281599
View directory record Official record
Conditions
HPV Infection, HPV 16 Infection, High Risk HPV, Cervical Cancer Screening, Cervical Cancer Cin Grade, Cervical Cancer (Early Detection), HPV, HPV (Human Papillomavirus)-Associated, HPV DNA, HPV Infections, Screening Test
Interventions
Q-Pad hrHPV Test System
Device
Lead sponsor
Qurasense
Industry
Eligibility
25 Years and older · Female only
Enrollment
450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
3
States / cities
New Haven, Connecticut • Minneapolis, Minnesota • Akron, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 20, 2026, 12:38 AM EDT
Not listed Not applicable Interventional

Comparing Strategies for Implementing Primary HPV Screening

NCT04371887
View directory record Official record
Conditions
Cervical Cancer, Human Papillomavirus, Health Knowledge, Attitudes, Practice, Health Care Utilization
Interventions
Local Tailoring
Other
Lead sponsor
Chun Chao
Other
Eligibility
21 Years to 70 Years
Enrollment
45,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Dec 30, 2021 · Synced Oct 20, 2026, 12:38 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Gemcitabine and Concurrent Radiation Followed by Adjuvant Hysterectomy in Bulky Stage Ib and IIa Cervical Carcinoma

NCT00184093
View directory record Official record
Conditions
Uterine Cervical Cancer
Interventions
Gemcitabine
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 15, 2017 · Synced Oct 20, 2026, 12:38 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Collection of Blood, Bone Marrow, Tumor, or Tissue Samples From Patients With Cancer to Study Drug Resistance

NCT00026663
View directory record Official record
Conditions
Renal Cell Carcinoma, Lung Carcinoma, Cervical Carcinoma
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2024 · Synced Oct 20, 2026, 12:38 AM EDT
Terminated Phase 3 Interventional Results available

Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer

NCT00262821
View directory record Official record
Conditions
Cervical Adenocarcinoma, Cervical Adenosquamous Cell Carcinoma, Cervical Squamous Cell Carcinoma, Stage IB Cervical Cancer, Stage IIA Cervical Cancer, Stage IIB Cervical Cancer, Stage III Cervical Cancer, Stage IVA Cervical Cancer
Interventions
cisplatin, tirapazamine
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
273
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 195 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Oct 20, 2026, 12:38 AM EDT
Completed Phase 1Phase 2 Interventional Results available

T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers

NCT02280811
View directory record Official record
Conditions
Vaginal Cancer, Cervical Cancer, Anal Cancer, Penile Cancer, Oropharyngeal Cancer
Interventions
Fludarabine, Cyclophosphamide, E6 TCR, Aldesleukin
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 6, 2017 · Synced Oct 20, 2026, 12:38 AM EDT
Completed Phase 1 Interventional

Phase I Study of Intravenous Triapine (IND # 68338) in Combination With Pelvic Radiation Therapy With or Without Weekly Intravenous Cisplatin Chemotherapy for Locally Advanced Cervical, Vaginal, or Pelvic Gynecologic Malignancies

NCT00335998
View directory record Official record
Conditions
Recurrent Cervical Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Vaginal Cancer, Recurrent Vulvar Cancer, Stage III Vaginal Cancer, Stage IIIA Cervical Cancer, Stage IIIA Ovarian Epithelial Cancer, Stage IIIA Vulvar Cancer, Stage IIIB Cervical Cancer, Stage IIIB Ovarian Epithelial Cancer, Stage IIIB Vulvar Cancer, Stage IIIC Ovarian Epithelial Cancer, Stage IIIC Vulvar Cancer, Stage IV Ovarian Epithelial Cancer, Stage IVA Cervical Cancer, Stage IVA Vaginal Cancer, Stage IVB Cervical Cancer, Stage IVB Vaginal Cancer
Interventions
triapine, laboratory biomarker analysis, external beam radiation therapy, brachytherapy, cisplatin, pharmacological study
Drug · Other · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 11, 2013 · Synced Oct 20, 2026, 12:38 AM EDT
Completed Phase 2 Interventional Results available

Bupropion in Helping Adults Stop Smoking

NCT00534001
View directory record Official record
Conditions
Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Kidney Cancer, Leukemia, Liver Cancer, Lung Cancer, Pancreatic Cancer, Tobacco Use Disorder
Interventions
bupropion hydrochloride, placebo
Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 20, 2026, 12:38 AM EDT
Terminated Phase 1 Interventional

Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors

NCT04301011
View directory record Official record
Conditions
Solid Tumor, Microsatellite Stable Colorectal Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Cervical Cancer, Melanoma (Skin), Cutaneous Squamous Cell Carcinoma, Mesothelioma, Renal Cell Carcinoma, Oropharynx Cancer
Interventions
TBio-6517, Pembrolizumab
Biological
Lead sponsor
Turnstone Biologics, Corp.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
8
States / cities
Phoenix, Arizona • Jacksonville, Florida • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Oct 20, 2026, 12:38 AM EDT
Completed No phase listed Observational

Compliance to Vaginal Dilation Therapy in Patients Who Have Undergone Radiation Therapy For Stage IB, Stage IIA, Stage IIB, Stage IIIA, or Stage IIIB Cervical Cancer or Stage IA, Stage IB, Stage IIA, or Stage IIB Endometrial Cancer

NCT00735514
View directory record Official record
Conditions
Cervical Cancer, Endometrial Cancer, Radiation Toxicity, Sexuality and Reproductive Issues
Interventions
compliance monitoring, questionnaire administration, assessment of therapy complications, management of therapy complications, psychosocial assessment and care
Behavioral · Other · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
8
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced Oct 20, 2026, 12:38 AM EDT
Terminated Phase 2 Interventional Results available

Pembrolizumab and Olaparib in Cervical Cancer Patients

NCT04483544
View directory record Official record
Conditions
Cervical Cancer, Cervical Carcinoma
Interventions
pembrolizumab, olaparib
Drug
Lead sponsor
Baptist Health South Florida
Other
Eligibility
18 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Miami, Florida • Plantation, Florida
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 20, 2026, 12:38 AM EDT